Cost-Effectiveness Comparison between Ibrutinib, Chemotherapy, and Chemoimmunotherapy in Front-Line Treatment of Chronic Lymphocytic Leukemia (CLL)

被引：2
|
作者：
Nabhan, Chadi [1 ]
Nero, Damion [2 ]
Lee, Choo Hyung [2 ]
Kish, Jonathan K. [2 ]
Mato, Anthony R. [3 ]
机构：
[1] Cardinal Hlth Specialty Solut, Dublin, OH USA
[2] Cardinal Hlth, Dublin, OH USA
[3] Mem Sloan Kettering Canc Ctr, Leukemia Serv, CLL Program, 1275 York Ave, New York, NY 10021 USA
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-118640
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4757
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Comparison of Costs and Health Care Resource Utilization (HRU) in Chronic Lymphocytic Leukemia (CLL) Patients Treated with Front-Line Ibrutinib or Chemoimmunotherapy
    Nabhan, Chadi
    Chung, Jessica
    Mato, Anthony R.
    Kish, Jonathan
    Nero, Damion
    BLOOD, 2017, 130
  • [2] Front-line chronic lymphocytic leukemia: The role of chemoimmunotherapy
    Kim, Myung Sun
    Prasad, Vinay
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (04) : 560 - 561
  • [3] Comparison of Time to Next Treatment, Health Care Resource Utilization, and Costs in Patients with Chronic Lymphocytic Leukemia Initiated on Front-line Ibrutinib or Chemoimmunotherapy
    Emond, Bruno
    Sundaram, Murali
    Romdhani, Hela
    Lefebvre, Patrick
    Wang, Song
    Mato, Anthony
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (12): : 763 - +
  • [4] Consolidation Treatment with Lenalidomide Following Front-line or Salvage Chemoimmunotherapy in Chronic Lymphocytic Leukemia
    Strati, Paolo
    Keating, Michael
    Burger, Jan
    O'Brien, Susan
    Wierda, William
    Estrov, Zeev
    Zacharian, Gracy
    Ferrajoli, Alessandra
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S299 - S300
  • [5] The Impact of Front-Line Ibrutinib Dose Reduction and Interruption on Outcomes in Chronic Lymphocytic Leukemia (CLL) Patients
    Rhodes, Joanna
    Barr, Paul M.
    Ujjani, Chaitra S.
    Nabhan, Chadi
    Tam, Constantine S.
    Jacobs, Ryan
    Lansigan, Frederick
    Hill, Brian T.
    Brander, Danielle M.
    Shadman, Mazyar
    Skarbnik, Alan P.
    Pu, Jeffrey J.
    Sehgal, Alison R.
    Pagel, John M.
    Allan, John N.
    Kennard, Kaitlin
    Cheson, Bruce D.
    Beach, Douglas F.
    Patel, Bhavisha
    Isaac, Krista
    Tuncer, Hande H.
    Furman, Richard R.
    Mato, Anthony R.
    BLOOD, 2017, 130
  • [6] Consolidation treatment with lenalidomide following front-line or salvage chemoimmunotherapy in chronic lymphocytic leukemia
    Strati, Paolo
    Keating, Michael J.
    Burger, Jan A.
    O'Brien, Susan M.
    Wierda, William G.
    Estrov, Zeev
    Zacharian, Gracy
    Ferrajoli, Alessandra
    HAEMATOLOGICA, 2017, 102 (12) : 494 - 496
  • [7] Consolidation Treatment with Lenalidomide Following Front-line or Salvage Chemoimmunotherapy in Chronic Lymphocytic Leukemia
    Strati, Paolo
    Keating, Michael J.
    Burger, Jan A.
    O'Brien, Susan M.
    Wierda, William G.
    Estrov, Zeev
    Zacharian, Gracy
    Ferrajoli, Alessandra
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (10): : S12 - S13
  • [8] Cost-Effectiveness of Ibrutinib as First-line Treatment for Older Patients With Chronic Lymphocytic Leukemia in Iran
    Fariman, Soroush
    Nasab, Fatemeh Momeni
    Faraji, Hoda
    Afzali, Monireh
    VALUE IN HEALTH REGIONAL ISSUES, 2023, 38 : 93 - 100
  • [9] Chronic Lymphocytic Leukemia: A Review of Front-line Treatment Options, With a Focus on Elderly CLL Patients
    O'Reilly, Alma
    Murphy, James
    Rawe, Sarah
    Garvey, Mary
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (04): : 249 - 256
  • [10] COST-EFFECTIVENESS OF BENDAMUSTINE VERSUS FLUDARABINE FOR FIRST LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN COLOMBIA
    Bertwistle, D.
    Munakata, J.
    Wehler, E.
    Leyva, V
    Ariza, J. G.
    Zambrano, C.
    Gonzalez, L.
    VALUE IN HEALTH, 2013, 16 (07) : A413 - A413
12345